This work builds on previous glycoproteomics data [8] and investigates further into GLUT1 expression across different BLCA stages and metastases, emphasizing the clinical relevance of its expression and identifying potentially targetable GLUT1 glycoforms in bladder cancer patients, opening an avenue for targeted intervention in chemotherapy/immunotherapy resistant or refractory patients. Here, SLC2A1 is linked to urinary bladder cancer.